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TO THE EDITOR
The new RAF inhibitor vemurafenib
represents one of the first specifi-
cally targeted drugs for melanoma
(Bollag et al., 2010; Flaherty et al.,
2010; Joseph et al., 2010). However,
some individuals receiving vemurafenib
develop eruptive squamous neo-
plasms such as keratoacanthomas (KAs)
(Chapman et al., 2011). KAs are
usually considered low-grade squa-
mous proliferations (Cribier et al.,
1999; Clausen et al., 2006), and are
often interpreted as a subtype of
squamous cell carcinoma (SCC). Their
clinical course involves rapid growth
followed by spontaneous involution.
The mechanism by which KAs
develop is still unknown. Improved
understanding of the molecular and
genetic basis of KA formation would
allow their improved management.
To investigate genes involved in the
development of KAs in patients receiv-
ing vemurafenib, we obtained biopsy
specimens and studied gene expression
profiles by a microarray approach; full
details are available in the Supplemen-
tary Material online. These biopsies
were originally obtained by theAbbreviations: KA, keratoacanthoma; MAP, mitogen-activated protein; SCC, squamous cell carcinoma
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submitting clinician and preserved in
formalin for standard paraffin embed-
ding and sectioning and histopathologi-
cal interpretation from the Pathology
Department. We extracted RNA from
the lesional cells in the paraffin block to
create complementary DNA libraries,
which were then screened using the
Affymetrix U133plus 2.0 array (Santa
Clara, CA). We compared profiles of
KAs that arose after drug treatment to
spontaneous KAs (arising in patients
who did not receive vemurafenib),
normal skin, and of classic cutaneous
SCC after confirming the original histo-
pathological diagnosis; five samples of
each type were analyzed and all KAs
were in the proliferative stage.
Unsupervised clustering of the most
varying gene expression probes demon-
strated that KA tumors were separable
from both cutaneous SCC and normal
skin (Figure 1a), but KAs from patients
with and without drug treatment were
not distinguishable from each other
(Figure 1b). Having observed these
overall trends using unsupervised analy-
sis, we used supervised analysis to con-
firm that although there were 260 signi-
ficantly differentially expressed probes
between drug-induced KA and SCC,
and 41 significantly differentially expre-
ssed probes between drug-induced KA
and normal skin, there were no probes
that were significantly differentially
expressed between drug-induced and
spontaneous KAs (Bonferroni-corrected
Student’s t-test P-value p0.01). We
concluded that drug-induced KA and
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Figure 1. Unsupervised clustering of tumor and normal samples. (a, top) Clustering of all samples (squamous cell carcinoma (SCC), normal skin, and
keratoacanthoma (KA)/KA-drug). (b, bottom) Clustering of KA-drug versus KA tumors only. Hierarchical clustering of the top 500 most varying probes (highest,
coefficient of variation) segregates normal samples from SCC samples and both from all KA samples (spontaneous and drug derived). The normal samples form a
tight cluster. SCC tumors show overall similarity to normal tissue, with some tumors more similar to normal tissue than others. KA tumors are a distinct sample
group, but the type of KA tumor does not clearly distinguish the observed gene expression pattern.
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spontaneous KA tumors have the same
expression profile.
Recent reports have indicated that
differences in mitogen-activated protein
(MAP) kinase gene expression are
potentially important for tumor progres-
sion (Packer et al., 2009; Joseph et al.,
2010; Nazarian et al., 2010; Poulikakos
et al., 2010). In our data sets, genes of
the MAP kinase pathway were not
overexpressed in either drug-induced
or spontaneous KA (relative to each
other or normal skin). To confirm this,
we used quantitative reverse transcrip-
tase–PCR to amplify several genes
within the MAP kinase pathway and
transforming growth factor-b receptor 1.
The results in Table 1 indicated no
significant difference in expression.
We next examined downstream
transcriptional targets of the MAP kinase
pathway, including CCND1, DUSP6,
SPRY2, ETV1, ETV5, FOSL1, and
CXCL1, genes described as directly
modulated by vemurafenib inhibition
in BRAF V600E melanomas (Packer
et al., 2009; Joseph et al., 2010). None
was found to be differentially expressed.
KAs and other squamous prolifera-
tions generally occur on sun-damaged
skin. The precise mechanisms that
underlie the initiation and growth of
these neoplasms remain unclear.
Vemurafenib can activate the MAP
kinase pathway in wild-type BRAF
melanoma in vitro, through either het-
erodimerization of CRAF with BRAF or
activation of wild-type BRAF through
NRAS (Heidorn et al., 2010; Joseph
et al., 2010; Nazarian et al., 2010;
Poulikakos et al., 2010). This effect is
transient and may last only a few hours
(Joseph et al., 2010). Side effects in
melanoma cells may be due to
unintended activation of the MAP
kinase or other pathways in wild-type
BRAF cells.
We found that in vemurafenib-asso-
ciated KAs mRNA levels downstream of
BRAF are not increased relative to
spontaneous KAs. These data suggest
that vemurafenib may accelerate a neo-
plastic process in susceptible or sun-
damaged keratinocytes, similar to the
processes underlying spontaneous KAs,
although any such activation is transi-
ent. Hence, by biopsy time, enhanced
activation of the MAP kinase pathway is
not seen and there is no increase in
transcripts of members of the MAP
kinase pathway or of downstream tar-
gets, despite continued therapy.
Another possibility is that vemurafe-
nib and similar molecules cause differ-
ent ‘‘off-target’’ effects that cause
activation through alternative mechan-
isms. The induced effects may be dose
dependent and additional studies
may define the threshold at which
KAs occur in patients receiving
vemurafenib or related agents. Recently,
Oberholzer et al. (2012) and Su et al.
(2012) have noted that HRAS mutations
are overrepresented in vemurafenib-
induced squamous neoplasms (in both
KA and SCC) compared with spontan-
eous ones, and the drug may induce
neoplastic proliferation in this setting.
One limitation of this study is the
small sample size analyzed; nonethe-
less, our findings indicate that KAs
associated with vemurafenib treatment
have similar genetic profiles to sponta-
neous KAs and similar expression of MAP
kinase pathway genes. These data sug-
gest that BRAF inhibitors may accelerate
a neoplastic process in susceptible
keratinocytes. However, any activation
appears transient and drug-associated
KAs behave similarly as spontaneous
KAs. Our results strongly suggest that
drug-induced KAs should be treated
in a manner similar to spontaneous
KAs. Although newer molecularly tar-
geted drugs are presented as highly
target specific, they may have ‘‘off-tar-
get’’ effects on other proteins. Further
study and monitoring will be impor-
tant to fully understand the underlying
mechanisms.
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Table 1. Fold differences in gene expression between the KA-drug and
spontaneous KA samples, along with RT–PCR results for gene expression for
main genes of the MAP kinase pathway and TGFbR1
Gene
Fold difference KA-drug
versus KA
P-value fold
difference
DDCT KA-drug versus
KA
P-value
DDCT
ARAF 1.039 0.366 0.30 0.39
BRAF 1.012 0.822 0.10 0.75
CRAF 1.057 0.439  0.70 0.24
HRAS 1.048 0.106 0.90 0.11
KRAS 1.092 0.322 1.50 0.11
NRAS 1.017 0.841 0.20 0.69
MEK 1.019 0.838 4.00 0.14
ERK 1.031 0.302 0.30 0.54
TGFbR1 1.07 0.531  2.00 0.07
Abbreviations: KA, keratoacanthoma; MAP, mitogen-activated protein; RT–PCR; reverse transcriptase–
PCR; TGFbR1, transforming growth factor b receptor 1.
The expression of correlated probes was averaged and collapsed onto the t-test P-value. As noted, there
is no significant difference in gene expression from the microarray data or from RT–PCR data. For genes
where multiple probes were available, the probe with smallest P-value is reported.
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TO THE EDITOR
Pseudoxanthoma elasticum (PXE;
OMIM#264800) is characterized by
progressive, late-onset, ectopic minera-
lization of elastic fibers, clinically affect-
ing skin, retina, and the cardiovascular
system with considerable morbidity and
occasional mortality (Neldner, 1988). It
is an autosomal recessive disorder with
a slight female preponderance and an
estimated prevalence of B1 in 50,000–
70,000. The clinical diagnosis is usually
made through recognition of characteri-
stic skin lesions, i.e., small, yellowish
papules on flexural areas progressively
coalescing into plaques of inelastic,
leathery skin. The cutaneous findings
are associated with angioid streaks in
the retina and mineralization of arterial
blood vessels. Adding to the diagnostic
difficulty is the considerable phenotypic
heterogeneity in age at onset and the
extent and severity of organ system
involvement. Since the identification of
mutations in the ATP-binding cassette,
subfamily C, member 6 gene (ABCC6)
as the genetic basis in the overwhelming
majority of families with PXE, tremen-
dous progress has been made in
understanding the molecular genetics,
clinical phenotypes, and pathogenesis
of this disease (Uitto et al., 2010).
Mutations in the ABCC6 gene under-
lie the classic form of PXE, and over 300
distinct mutations representing over
1,000 mutant alleles have been reported
(Uitto et al., 2010). However, no
apparent correlation has been establi-
shed between PXE phenotypes and the
nature or the position of the mutations
in ABCC6 (Pfendner et al., 2007).
Genetic variations in gamma-glutamyl
carboxylase (GGCX) (Vanakker et al.,
2007; Li et al., 2009), secreted phospho-
protein 1 (SPP1) (Hendig et al., 2007),
and xylosyltransferase I (XYLT) (Schon
et al., 2006) genes, together with
environmental risk factors such as diet
(LaRusso et al., 2009), appear to modify
the phenotype with respect to the age at
onset and the extent and severity of
organ involvement in PXE.
Understanding of the mechanisms
underlying PXE has been advanced by
the development of targeted mutant
mice with genetic, histopathological,
and ultrastructural features similar to
those in patients with PXE (Gorgels
et al., 2005; Klement et al., 2005). A
characteristic finding in the targeted
mutant mouse (B6;129S1/SvImJ-
Abcc6tm1Jfk) is the mineralization of the
vibrissae dermal sheaths, the principal
components of which were calcium and
phosphorus (Kavukcuoglu et al., 2012).
This specialized hair follicle type is not
found in humans, and mineralization
of the vibrissae dermal sheath is very
unusual in mice. The genetic back-
ground of mice can modify phenotypes
associated with a single gene mutation
as is the case with this Abcc6tm1Jfk-null
Abbreviations: ATP-binding cassette, subfamily C, member 6 (gene symbol: Abcc6, mice; ABCC6, human;
protein symbol for both: ABCC6); secreted phosphoprotein 1 (gene symbol: SPP1, human); SUMO/sentrin-
specific peptidase 6 (gene symbol: SENP6, human; Senp6, mouse); xylosyltransferase I (gene symbol:
XYLT, human; Xylt1 and 2, mouse); Casr, calcium-sensing receptor; DCC, dystrophic cardiac calcinosis;
PXE, pseudoxanthoma elasticum; SNP, single-nucleotide polymorphism
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